Pliant Therapeutics, Inc. (NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...

The disease can cause it to become harder and harder to breathe - and it's key you keep an eye out for symptoms ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Long-term exposure to toxic air pollutants, particularly carcinogens like benzene, formaldehyde, and polycyclic aromatic ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...

If you have a cough and are putting it down to 'just you' or 'that illness' you've had for weeks, you should see a GP, a ...

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...